Back to search

Article

Growth trajectories in Pediatric Cystic Fibrosis Population on Elexacaftor-Tezacaftor-Ivacaftor: Real-Life Data

2024-11-18

Abstract excerpt

<h4>Background: </h4> Cystic fibrosis (CF) is a multi-system disease that causes chronic respiratory failure, malnutrition and poor growth as a result of a negative energy balance due to maldigestion and malabsorption. Achieving linear growth and height above the 50 th percentile is associated with improved lung function. In October 2022, the use of Elexacaftor/Tezacaftor/Ivacaftor (ETI) was approved for children...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
50b2e3ed-3dae-5e13-82d0-8789b6126a15
DOI
10.22541/au.173195834.49805192/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Growth trajectories in Pediatric Cystic Fibrosis Population on Elexacaftor-Tezacaftor-Ivacaftor: Real-Life DataDOI 10.22541/au.173195834.49805192/v1
A retrospective analysis of clinical parameters, safety and tolerability of Elexacaftor/Tezacaftor/Ivacaftor in a cohort of patients aged 6-17 years with cystic fibrosisSemantic proximity
Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal studySemantic proximity
Heterogeneity of weight gain after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosisSemantic proximity
Elexacaftor/tezacaftor/ivacaftor in children aged 6–11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24‐week observational studySemantic proximity
Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor.Semantic proximity
Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis.Semantic proximity
Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.Semantic proximity
Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.Semantic proximity
Changes in nutrition and growth status in young children in the first 12 weeks of ivacaftor therapy.Semantic proximity
Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.Semantic proximity
Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review.Semantic proximity
Weight a minute: Exploring the effect on weight and body composition after the initiation of elexacaftor/tezacaftor/ivacaftor in adults with CF.Semantic proximity
Select a neighboring publication to make it the new centre.